Your browser version may not work well with NCBI's Web applications. More information here...
1: J Hematol Oncol. 2008 Oct 29;1(1):20. [Epub ahead of print]
Related Articles, Links
Click here to read
First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting.

Molckovsky A, Siu LL.

ABSTRACT: This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine.

PMID: 18959794 [PubMed - as supplied by publisher]